Investigation of the Effects of Angling as Supportive Therapy in Schizophrenia Treatment on Serum Parameters, Anxiety, Depression, and Quality of Life
Angling as a Supportive Therapy in the Treatment of Schizophrenia
This study aims to evaluate the effects of recreational fishing (angling) as a supportive therapeutic intervention in individuals diagnosed with schizophrenia. Schizophrenia is a chronic psychiatric disorder characterized by disturbances in thinking, perception, emotion, and behavior, often accompanied by negative symptoms such as social withdrawal, anhedonia, and cognitive impairment, which significantly reduce quality of life.
Recreational activities, particularly those involving nature-based engagement, have been shown to support psychological well-being through stress reduction, improved attention, and enhanced mood regulation. Angling is considered a mindfulness-like recreational activity that promotes relaxation, concentration, and emotional regulation, potentially offering benefits for individuals with psychiatric conditions.
In this randomized controlled study, participants with schizophrenia will engage in a structured recreational fishing program in addition to standard care. The effects of the intervention will be evaluated on biochemical serum parameters, anxiety and depression levels, and quality of life outcomes. The study also aims to assess the psychosocial well-being of participants and determine the feasibility of integrating angling as an adjunctive non-pharmacological intervention in schizophrenia care.
The findings are expected to contribute to evidence-based complementary treatment approaches in psychiatric rehabilitation.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Center
-
Elâzığ, Center, Turquie (Türkiye), 25240
- Recrutement
- Fırat University
-
Contact:
- Gülcan B Bahçecioğlu Turan
- Numéro de téléphone: 506 557 60 86
- E-mail: gulcanbahcecioglu@firat.edu.tr
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
La description
Inclusion Criteria:
- Adults aged 18 years and older
- Able to communicate verbally
- Diagnosed with schizophrenia
- Able to provide written informed consent
Exclusion Criteria:
- Presence of comorbid psychiatric disorders other than schizophrenia
- Patients in the acute psychotic (attack) phase
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: Contrôler
|
|
|
Expérimental: recreational fishing (angling)
|
Fishing will be done.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Quality of Life Scale for Schizophrenia Patients
Délai: Baseline and immediately after the 8-week intervention.
|
Developed by Heinrich et al. to assess the quality of life of schizophrenia patients, the Turkish validity and reliability study was conducted by Soygür et al.
Administered in a semi-structured interview format, the scale evaluates the individual's symptoms and level of functioning over the past four weeks.
It consists of 21 items and four sub-dimensions: interpersonal relationships, occupational role, mental symptoms, and daily activities.
Scores on the scale range from 0 to 126, with higher scores indicating better quality of life.
|
Baseline and immediately after the 8-week intervention.
|
|
UCLA Loneliness Scale
Délai: Baseline and immediately after the 8-week intervention.
|
The UCLA Loneliness Scale-Short Form (ULS-8) is an 8-item self-report instrument used to assess perceived loneliness.
Each item is rated on a 4-point Likert scale ranging from 1 ("Never") to 4 ("Always").
Two items are reverse scored.
Total scores range from 8 to 32, with higher scores indicating greater perceived loneliness.
|
Baseline and immediately after the 8-week intervention.
|
|
The Positive and Negative Syndrome Scale
Délai: Baseline and immediately after the 8-week intervention.
|
The Positive and Negative Syndrome Scale : he Positive and Negative Syndrome Scale (PANSS), developed by Kay et al., is a semi-structured clinician-rated instrument consisting of 30 items scored on a 7-point scale (1 = absent to 7 = extreme).
The scale comprises three subscales: positive symptoms (7 items; score range: 7-49), negative symptoms (7 items; score range: 7-49), and general psychopathology (16 items; score range: 16-112).
Total PANSS scores range from 30 to 210, with higher scores indicating more severe psychopathology and poorer clinical status.
|
Baseline and immediately after the 8-week intervention.
|
|
Serum Beta-Endorphin Concentration
Délai: Baseline and immediately after the 8-week intervention.
|
Venous blood samples will be collected to measure serum beta-endorphin concentration.
Changes in serum beta-endorphin levels will be evaluated to assess the biological effects of the intervention.
|
Baseline and immediately after the 8-week intervention.
|
|
Serum Serotonin Concentration
Délai: Baseline and immediately after the 8-week intervention.
|
Venous blood samples will be collected to measure serum serotonin concentration.
Changes in serum serotonin levels will be evaluated to assess the biological effects of the intervention.
|
Baseline and immediately after the 8-week intervention.
|
|
Serum Cortisol Concentration
Délai: Baseline and immediately after the 8-week intervention.
|
Venous blood samples will be collected to measure serum cortisol concentration.
Changes in serum cortisol levels will be evaluated to assess the biological effects of the intervention.
|
Baseline and immediately after the 8-week intervention.
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2026/09-43
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .